Compare Merck & Co., Inc. (MRK) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Royal Caribbean Cruises Ltd — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Royal Caribbean Cruises Ltd trades at $261.61 (market cap $70.74B). The key difference: Merck & Co., Inc. is far larger — about 5.2× Royal Caribbean Cruises Ltd's market cap, and Merck & Co., Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| MRK | RCL | |
|---|---|---|
Market Cap | $366.28B | $70.74B |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $350.23 |
52-Week Low | $77.60 | $246.71 |
Enterprise Value | $413.04B | $93.38B |
Dividend Yield | 2.29% | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Royal Caribbean (RCL) trades at $264.5, down 0.26% on the day, with technical indicators showing a bearish trend near key support at $261. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $4.21 vs. $3.98, revenue growth to $17.93B in 2025, and robust profitability margins. Recent news highlights dividend declarations and institutional buying interest despite oil price concerns impacting cruise stocks.
The outlook remains positive with analyst consensus price target of $367.83 suggesting 39% upside, supported by earnings momentum and institutional accumulation. Key risks include oil price volatility affecting fuel costs and competitive pressures in the cruise industry. The stock presents a growth opportunity with solid fundamentals but requires monitoring of macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
